Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals’ Hib-MenC

Neisseria meningitidis

Evaluation of Post Infectious Inflammatory Reaction (PIIR) Concerning Children After Streptococcus Pneumoniae, Streptococcus Pyogenes and Neisseria Meningococcus Invasive Infection Investigating Meningococcal Vaccines in Adults Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals’ Hib-MenC & to Evaluate Persistence up to 5 Years. Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals’ Hib-MenC Primary & Booster Immunogenicity Study of GSK Biologicals’ Hib-MenC Versus a Licensed Men-C Vaccine Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine Dose Comparison Study of Menactra® in US Children Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals’ Hib-MenCY-TT Vaccine Compared to ActHIB Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vaccinated MenBVac® (Extension EFFIVAC) Neisseria Meningitidis Burden of Disease Study Study to Assess Oropharyngeal Carriage of N. Meningitidis in South Australian School Leavers